Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TauRx Chairman Claude Wischik On Waging A Battle Against Alzheimer’s Disease His Way: An Interview With PharmAsia News (Part 2 of 2)

This article was originally published in PharmAsia News

Executive Summary

Claude Wischik has spent more than a decade working on a drug that would inhibit the aggregation of tau tangles in the brain, and says his work has put the Singapore-based company TauRx Pharmaceuticals Ltd. onto a path that could produce the world’s best-selling drug, surpassing Pfizer Inc.’s Lipitor (atorvastatin).

Advertisement

Related Content

Lilly Expands Bet on Tau By Buying Siemens’ Alzheimer’s Imaging Portfolio
Merck Inks Deal For Second Alzheimer’s Test, This Time With Luminex
Efficacy Signal For Lilly’s Solanezumab Stirs The Alzheimer’s Pot
Bapineuzumab Failure Raises More Doubts About Beta Amyloid Approach In Alzheimer’s

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC084338

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel